^
Association details:
| Biomarker: | FGFR1 amplification + RAF1 amplification + MYC amplification |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Votrient (pazopanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC
Excerpt:
...a second liquid biopsy was carried out, demonstrating a molecular response to the treatment with a spectacular decrease of molecular tumor burden, with FGFR1 amplification undetectable in plasma cfDNA (Fig 2), as well as MYC and RAF1 amplifications...Pazopanib was maintained at the same dose because of clinical benefit, sustained radiographic response, and undetectability of FGFR amplification in serial liquid biopsies.
DOI:
10.1200/PO.19.00243
Test:
